Altimmune Stock Tanks On Double Bad News From COVID-19 Program
Altimmune Inc (NASDAQ:ALT) revealed it would hit the pause button on its immunomodulatory candidate for COVID-19, dubbed T-COVID, citing enrollment challenges.…
3 Stocks To Watch Today Based On High Retail-Investor Interest
The following stocks are attracting high retail-investor interest on social media early Wednesday.
Altimmune Says Has Been Unable To enroll Subjects In Final Cohort Of T-COVID Study, Will Terminate Further Enrollment And Evaluate Options For T-COVID
T-COVID Update
The Phase 1/2 trial completed dosing in 2 of the 3 planned dose cohorts. The first 2 cohorts were designed to assess the safety of T-COVID treatment and were comprised of COVID-19 infected patients 49
The Week Ahead In Biotech: Mediwound, Provention FDA Decisions, IPOs, Pending Clinical Readouts In Focus
Biotech stocks reversed course and closed the week ended June 25 higher, thanks to the positive broader market sentiment.
48 Biggest Movers From Yesterday
Gainers
Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront.
Altimmune’s Stock Trades In A Double Bottom Pattern: What’s Next?
Altimmune Inc. (NASDAQ: ALT) shares traded higher after the company announced data from its ALT-801 Phase 1 Trial in overweight and obese volunteers. The company announced that weight loss of 5.4% was achieved at six weeks with a weekly dose of 1.8mg.
JMP Securities Maintains Market Outperform on Altimmune, Raises Price Target to $53
JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ: ALT) with a Market Outperform and raises the price target from $45 to $53.JMP Securities analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and raise
The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 15)
Altimmune’s ALT-801 Achieves 5.4% Weight Loss Surpassing Pre-Established Target Of 2%
Altimmune Inc (NASDAQ: ALT) announced results from a prespecified 6-week interim analysis of its Phase 1 trial of ALT-801 in healthy, overweight, and obese volunteers.
The study is currently being conducted in Australia.